Genetic and pharmacological PARP inhibition reduces axonal degeneration in C. elegans models of ALS

Axonal degeneration is observed in early stages of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). This degeneration generally precedes apoptosis and therefore may be a promising therapeutic target. An increasing number of genes have been identified to actively reg...

Full description

Saved in:
Bibliographic Details
Published inHuman molecular genetics Vol. 31; no. 19; pp. 3313 - 3324
Main Authors Tossing, Gilles, Livernoche, Raphaël, Maios, Claudia, Bretonneau, Constantin, Labarre, Audrey, Parker, J Alex
Format Journal Article
LanguageEnglish
Published England 29.09.2022
Online AccessGet full text

Cover

More Information
Summary:Axonal degeneration is observed in early stages of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). This degeneration generally precedes apoptosis and therefore may be a promising therapeutic target. An increasing number of genes have been identified to actively regulate axonal degeneration and regeneration, however, only a few potential therapeutic targets have been identified in the context of neurodegenerative diseases. Here we investigate DLK-1, a major axonal regeneration pathway and its contribution to axonal degeneration phenotypes in several C. elegans ALS models. From this pathway, we identified the PAR polymerases (PARP) PARP-1 and PARP-2 as the most consistent modifiers of axonal degeneration in our models of ALS. Genetic and pharmacological inhibition of PARP-1 and PARP-2 reduces axonal degeneration and improves related motor phenotypes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0964-6906
1460-2083
DOI:10.1093/hmg/ddac116